Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences最新文献

{"title":"Advancement in neutrophil-based drug delivery systems.","authors":"Zihan Zhou, Longguang Tang","doi":"10.3724/zdxbyxb-2025-0093","DOIUrl":"https://doi.org/10.3724/zdxbyxb-2025-0093","url":null,"abstract":"<p><p>Neutrophils, as the most abundant immune cells in the human body, possess the inherent ability to rapidly migrate to sites of inflammation or infection. Novel drug delivery systems leveraging neutrophils capitalize on their natural targeting and phagocytic capabilities to achieve precise drug delivery. Efficient drug loading into neutrophils within neutrophil-based delivery systems can be achieved through physical adsorption, chemical conjugation, and phagocytosis. Design strategies emphasize carrier selection and targeting ligand design to enhance delivery precision. Compared to traditional drug delivery systems, neutrophil-based systems offer significant advantages, including excellent biocompatibility and strong tissue penetration. These properties can significantly improve drug bioavailability and reduce adverse reactions associated with non-target tissue accumulation. However, the system also faces several challenges requiring resolution, such as difficulties in cell collection and preservation, the need for stability optimization, difficulties for large-scale production, and a lengthy clinical translation cycle. In disease treatment applications, neutrophil-based drug delivery systems enable the precise delivery of anti-cancer drugs to tumor sites, potentially disrupting the immunosuppression of tumor microenvironment and enhancing therapeutic efficacy. For brain diseases, their unique ability to cross the blood-brain barrier facilitates effective drug delivery. In chronic inflammatory diseases, they can precisely deliver anti-inflammatory agents to mitigate inflammation. Performance enhancements for neutrophil-based systems, such as the development of novel nanomaterials and optimization of targeting ligand affinity, aim to improve the accuracy and efficiency of drug delivery. This review comprehensively explores the design strategies, advantages, challenges, and future directions of neutrophil-based drug delivery systems. It summarizes research progress in disease treatment applications, aiming to offer key insights for the development of novel drug delivery systems and thus advancing precision medicine and targeted therapy.</p>","PeriodicalId":24007,"journal":{"name":"Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences","volume":" ","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144638236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances of inhalable nano-formulations.","authors":"Yinjia Luo, Xiao Yue, Ziyu Zhao, Xuejuan Zhang","doi":"10.3724/zdxbyxb-2024-0650","DOIUrl":"https://doi.org/10.3724/zdxbyxb-2024-0650","url":null,"abstract":"<p><p>Nano-drug delivery systems (NDDSs) offer significant benefits, including high specific surface area, structural and functional diversity, and surface modifiability. When further engineered into inhalable nano-formulations, they can facilitate precise pulmonary drug delivery, enhance pulmonary bioavailability, and improve therapeutic efficacy. The nebulization stability of nano-drugs can be enhanced through structure optimization, surface modification, dispersion medium optimization, and device refinement. Furthermore, pulmonary delivery efficiency is improved by strategies such as employing blending excipients to enhance the re-dispersibility of nanoparticle agglomerates, optimizing microcarrier design, and innovating preparation processes. This review summarizes inhalable nano-formulations for the treatment of respiratory diseases, highlighting the key challenges and corresponding strategies encountered in combining NDDSs with inhalation drug delivery systems. It aims to provide a reference for the future development of inhalable nano-formulations.</p>","PeriodicalId":24007,"journal":{"name":"Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences","volume":" ","pages":"1-11"},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical efficacy and safety of transcatheter aortic valve replacement for patients with severe pure native aortic regurgitation.","authors":"Jiantao Chen, Yi Zhang, Kangni Feng, Suiqing Huang, Hanri Xiao, Mengya Liang, Zhongkai Wu","doi":"10.3724/zdxbyxb-2024-0515","DOIUrl":"https://doi.org/10.3724/zdxbyxb-2024-0515","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the early clinical efficacy and safety of trans-catheter aortic valve replacement (TAVR) for patients with severe pure native aortic regurgitation (PNAR).</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 48 PNAR patients who underwent TAVR at the Department of Cardiac Surgery, the First Affiliated Hospital of Sun Yat-sen University between March 2019 and February 2025, including 25 cases with transfemoral approach (TF-TAVR group) and 23 cases with transapical approach (TA-TAVR group). Efficacy and safety were assessed by analyzing baseline characteristics, all-cause mortality, and procedure-related complications.</p><p><strong>Results: </strong>Compared with the TA-TAVR group, the TF-TAVR group exhibited significantly smaller aortic annulus circumference and diameter, left ventricular outflow tract circumference and diameter, diameters of the left, right, and non-coronary sinuses, and sinotubular junction (STJ) diameter, with a shorter distance from the STJ to the aortic valve basal ring plane (all <i>P</i><0.01). Additionally, the TF-TAVR group had a smaller annulus angle (<i>P</i><0.05), and showed a deeper prosthesis implantation depth relative to the aortic valve basal ring plane (<i>P</i><0.01). Post-TAVR, both groups demonstrated significant improvement in left ventricular end-diastolic diameter (both <i>P</i><0.05), but only the TA-TAVR group showed significant reduction in left ventricular end-systolic diameter (<i>P</i><0.05). The overall technical success rate was 91.67%, and device success rate was 83.33%. For primary outcomes, in-hospital mortality occurred in 2 patients (4.17%). No additional deaths were reported at 60 d or 90 d after surgery. During 90-180 d after surgery, one patient in the TF-TAVR group (4.76%) died of sudden cardiac death, and one in the TA-TAVR group (6.25%) died of gastrointestinal bleeding. During 180 d-1 year after surgery, one patient in the TF-TAVR group (9.09%) died of low cardiac output syndrome. No statistically significant differences were observed in 1-year Kaplan-Meier survival curves between two groups (<i>P</i>>0.05). No conduction block events occurred in TA-TAVR group, while high-grade atrioventricular block, left bundle branch block, permanent pacemaker implantation occurred in TF-TAVR group during hospitalization or 1-year follow-up (12.00%, 4.00%, and 12.00%, respectively).</p><p><strong>Conclusions: </strong>TAVR demonstrates high success rates and acceptable safety for severe PNAR patients who are unable to undergo traditional surgical procedures. Although TF-TAVR may face more challenges in certain complex cases than TA-TAVR, the overall outcomes are promising.</p>","PeriodicalId":24007,"journal":{"name":"Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences","volume":" ","pages":"1-12"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144555149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress on carboxyl-substituted phthalocyanine photosen-sitizers and their drug delivery systems for photodynamic therapy.","authors":"Dan Shen, Hongjie Huang, Jincan Chen, Bowen Li, Zhuo Chen","doi":"10.3724/zdxbyxb-2024-0687","DOIUrl":"https://doi.org/10.3724/zdxbyxb-2024-0687","url":null,"abstract":"<p><p>Photodynamic therapy (PDT), a photochemical treatment modality centered on photosensitizers, is increasingly demonstrating its significant value in treating malignant tumors and microbial infections. Phthalocyanine compounds, as outstanding representatives of traditional photosensitizers, have attracted considerable attention due to their excellent photophysical and photochemical properties. However, the hydrophobicity of their macrocyclic aromatic planes often leads to intermolecular aggregation, reducing reactive oxygen species (ROS) generation efficiency and impairing drug bioavailability. To address this limitation, carboxylation of the phthalocyanine ring periphery provides amidation sites, facilitating further functionalization and enabling combination with diverse materials, thereby expanding the application potential of phthalocyanine photosensitizers. Additionally, carboxyl substitution enhances the biocompatibility of phthalocyanine photosensitizers and helps mitigate the aggregation problem caused by their hydrophobic nature. Modification strategies for carboxyl-substituted phthalocyanines span multiple fields, including organic chemistry, biomacromolecules, polymeric materials, and inorganic nanomaterials. Based on our team's research, this review delves into the advances in preparation techniques and delivery systems for carboxyl-substituted phthalocyanine photosensitizers and their derivatives. It comprehensively analyzes their advantages and challenges in PDT and imaging systems, aiming to provide technical support and novel perspectives for the development and application of this class of photosensitizers, promote the advancement of PDT in fields such as malignant tumor and microbial infection treatment, drive innovation and application of related technologies, and offer more effective means and strategies for addressing clinical challenges.</p>","PeriodicalId":24007,"journal":{"name":"Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences","volume":" ","pages":"1-11"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144555150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research progress on lipid nanoparticle messenger RNA delivery system.","authors":"Shun He, Shuai Liu","doi":"10.3724/zdxbyxb-2024-0709","DOIUrl":"https://doi.org/10.3724/zdxbyxb-2024-0709","url":null,"abstract":"<p><p>mRNA therapeutic is a biotechnology that involves delivering <i>in vitro</i> transcribed mRNA into specific cells to produce target proteins for the treatment or prevention of diseases. However, the development of mRNA therapeutics relies largely on mRNA delivery systems, and lipid nanoparticles (LNPs) represent the most widely used mRNA carriers in clinical applications. Composed of ionizable lipids, phospholipids, cholesterol, and polyethylene glycol-lipids, LNPs can address critical challenges in mRNA drug development, such as poor <i>in vivo</i> stability and the difficulty in crossing biological barriers. Ultimately, LNPs enable safe, efficient, and targeted mRNA delivery to the liver, lung, spleen, and so on. This review outlines the roles of the four lipid components in LNPs for mRNA delivery. Then it introduces targeted mRNA delivery to various organs/tissues such as the liver, lung, spleen, pancreas, bone marrow, and placenta, using strategies of antibody modification, lipid structure alteration, and specialized administration routes. Additionally, this review discusses the applications and challenges of LNP-based mRNA therapeutics in disease treatment, aiming to provide insights for the clinical translation of mRNA therapies and the further innovation of LNP delivery systems.</p>","PeriodicalId":24007,"journal":{"name":"Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences","volume":" ","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144226908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[<i>In vitro</i> cultured calculus bovis alleviates cerebral ischemia/reperfusion injury through regulating microglial polarization and inhibiting NLRP3].","authors":"Tanlu Chu, Wei Zhang, Jingwen Chen, Zeyue Pan, Lingfeng Wang, Xiaoming Zhong, Fengmei Qiu, Zhen Huang","doi":"10.3724/zdxbyxb-2024-0573","DOIUrl":"10.3724/zdxbyxb-2024-0573","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the effect of <i>in vitro</i> cultured calculus bovis (ICCB) on cerebral ischemia/reperfusion injury (CIRI) and its mechanism.</p><p><strong>Methods: </strong>A CIRI rat model and a cell model were induced by middle cerebral artery occlusion (MCAO) in Sprague Dawley rats and oxygen glucose deprivation/reperfusion (OGD/R) in BV2 cells, respectively. The CIRI rat model was evaluated using the modified neurological severity score (mNSS), brain water content, and cerebral infarction volume after 1.5 h of ischemia followed by 72 h of reperfusion. Histopathological changes in the cortex and hippocampal CA1 region were observed with hematoxylin and eosin staining. Microglial polarization and NOD-like receptor thermal protein domain associated protein (NLRP) 3 inflammasome expression in the cortex were examined by immunofluorescence. BV2 cell viability was measured via MTT assay after treatment with ICCB and Nigericin. The expressions of NLRP3, ASC, caspase-1 proteins and inflammatory cytokines were detected with Western blotting in OGD/R treated BV2 cells (0.5 h OGD+24 h reperfusion) and in cells pretreated with Nigericin for 24 h.</p><p><strong>Results: </strong>ICCB treatment significantly improved neurological function, reduced cerebral infarct volume and brain water content, and mitigated pathological damage in the cortical and hippocampal CA1 regions of rats subjected to CIRI (all <i>P</i><0.05). ICCB promoted the transition of cortical microglia from M1 to M2 phenotypes and suppressed NLRP3 activation in microglial cells (all <i>P</i><0.01). ICCB significantly down-regulated the expression of NLRP3, ASC, and caspase-1 proteins, and reduced the secretion of IL-18 and IL-1β in BV2 cells of OGD/R model (all <i>P</i><0.01). In addition, Nigericin significantly reversed the salvage effect of ICCB on model cells (both <i>P</i><0.01) and the modulation of inflammatory cytokines (<i>P</i><0.05).</p><p><strong>Conclusions: </strong>ICCB exerts a protective effect against CIRI by mitigating neuroinflammation, through the reduction of M1 microglial polarization, promotion of M2 conversion, and suppression of the NLRP3/ASC/caspase-1 signaling pathway.</p>","PeriodicalId":24007,"journal":{"name":"Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences","volume":" ","pages":"360-371"},"PeriodicalIF":0.0,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12176533/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143597977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[<i>Scleromitrion diffusum</i> reverses epithelial-mesenchymal transi-tion of gastric mucosa in rats with gastric precancerous lesions].","authors":"Luping Ma, Xin Zuo, Weikai Zhu, Jiyan Li, Yanyan Zhao, Jingyuan Zhang, Hui Shen","doi":"10.3724/zdxbyxb-2024-0536","DOIUrl":"10.3724/zdxbyxb-2024-0536","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the effect of <i>Scleromitrion diffusum</i> on gastric mucosal epithelial-mesenchymal transition (EMT) in rats with gastric precancerous lesion.</p><p><strong>Methods: </strong>Fifty SD rats were randomly divided into blank control group (<i>n</i>=11), model control group (<i>n</i>=13), <i>Scleromitrion diffusum</i> (SD) group (<i>n</i>=13) and vitase group (<i>n</i>=13). Gastric precancerous lesion animal model was prepared by 1-methyl-3-nitro-1-nitrosoguanidine complex polyfactor method, and the drugs were administrated by gavage once a day for 6 weeks. The pathological changes of gastric mucosa were observed with hematoxylin and eosin staining, the expression of EMT marker proteins were detected with immunohistochemical staining and Western blotting.</p><p><strong>Results: </strong>Compared with the model control group, the gastric mucosal injury was significantly attenuated in the <i>Scleromitrion diffusum</i> group, the mucosal tissue structure gradually recovered, the saccular expansion area was reduced, and the inflammatory infiltration was ameliorated. The expression of epithelial cadherin was higher, and the expression of neural cadherin and vimentin in the <i>Scleromitrion diffusum</i> group were lower than those of model control group (all <i>P</i><0.05).</p><p><strong>Conclusions: </strong><i>Scleromitrion diffusum</i> can ameliorate gastric mucosal injury in rats with gastric precancerous lesion by reversing the EMT.</p>","PeriodicalId":24007,"journal":{"name":"Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences","volume":" ","pages":"342-349"},"PeriodicalIF":0.0,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12176539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143804252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Shenge powder inhibits myocardial fibrosis in rats with post-myocardial infarction heart failure through LOXL2/TGF-β1/IL-11 signaling pathway].","authors":"Hang Xie, Boyong Qiu, Haitao Li, Ruoyu Shi","doi":"10.3724/zdxbyxb-2024-0606","DOIUrl":"10.3724/zdxbyxb-2024-0606","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the effect of Shenge powder (SGP) on myocardial fibrosis in rats with heart failure after myocardial infarction and its relation with lysyl oxidase like protein 2 (LOXL2)/transforming growth factor-β1 (TGF-β1)/IL-11 signaling pathway.</p><p><strong>Methods: </strong>Seventy-two SPF male SD rats were divided into blank control group, model control group, SGP small dose group, SGP large dose group, positive control group, SGP large dose+LOXL2 activator group, with 12 rats in each group. Except for the blank control group, post-myocardial infarction heart failure was induced by coronary constriction. Corresponding treatments were given immediately after successful modeling, once a day for 4 weeks. Left ventricular fractional shortening (LVFS) and left ventricular ejection fraction (LVEF) in rats were detected by color Doppler ultrasound imaging. Levels of IL-1β and IL-6 in serum were analyzed by ELISA method. Myocardial collagen volume fraction (CVF) was evaluated by Masson staining. Expressions of collagen Ⅰ and α-smooth muscle actin (α-SMA) in myocardial tissue were detected by immunohistochemical staining. The mRNA expressions of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase 1 (TIMP-1) in myocardial tissue were detected by qRT-PCR. Expression of LOXL2, TGF-β1, and IL-11 proteins in myocardial tissue were detected by Western blotting.</p><p><strong>Results: </strong>Compared with the blank control group, the LVFS and LVEF of the model control group decreased, the levels of serum IL-6 and IL-1β elevated, and the CVF value, the expressions of collagen Ⅰ and α-SMA in myocardial tissue, <i>MMP</i>-<i>9</i> and <i>TIMP</i>-<i>1</i> mRNA, and LOXL2, TGF-β1, IL-11 proteins increased (all <i>P</i><0.05). Compared with the model control group, the LVFS and LVEF of SGP small dose group, SGP large dose group and positive control group increased, the levels of serum IL-6 and IL-1β decreased, and the CVF value, the expressions of collagen Ⅰ and α-SMA in myocardial tissue, <i>MMP</i>-<i>9</i> and <i>TIMP</i>-<i>1</i> mRNA, and LOXL2, TGF-β1, IL-11 proteins decreased (all <i>P</i><0.05); while LOXL2 activator reversed the improvement effect of high-dose SGP on myocardial fibrosis in heart failure rats after myocardial infarction.</p><p><strong>Conclusions: </strong>Shenge powder may inhibit myocardial fibrosis in heart failure rats after myocardial infarction by inhibiting the LOXL2/TGF-β1/IL-11 pathway.</p>","PeriodicalId":24007,"journal":{"name":"Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences","volume":" ","pages":"350-359"},"PeriodicalIF":0.0,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12176534/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Short-term outcomes of transcatheter pulmonary valve replacement with Venus-P valve in patients with moderate-to-severe pulmonary regurgitation and right ventricular systolic dysfunction].","authors":"Haiyue Xie, Wenhao Zhu, Zhiyuan Xia, Gejun Zhang","doi":"10.3724/zdxbyxb-2024-0493","DOIUrl":"10.3724/zdxbyxb-2024-0493","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the short-term outcomes of transcatheter pulmonary valve replacement (TPVR) using the Venus-P valve in patients with moderate-to-severe pulmonary regurgitation and right ventricular systolic dysfunction (RVSD) following surgical repair of complex congenital heart disease.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on patients undergoing Venus-P valve implantation (TPVR group, <i>n</i>=28) or surgical pulmonary valve replacement (SPVR group, <i>n</i>=19) at Fuwai Hospital between February 2014 and February 2024. All patients had moderate-to-severe pulmonary regurgitation with right ventricular ejection fraction less than 45% preoperatively. Postoperative pulmonary valve function and ventricular parameters were assessed at discharge and during a 6-month follow-up.</p><p><strong>Results: </strong>All procedures were successfully completed with no early mortality. At 6 months, the TPVR group demonstrated significantly lower pulmonary valve transvalvular pressure gradients compared to the SPVR group (<i>P</i><0.05). Both groups exhibited significant improvements from baseline in New York Heart Association (NYHA) functional class, biventricular ejection fractions, and right ventricular end-diastolic volume index (all <i>P</i><0.05). The reduction in right ventricular end-diastolic diameter differed between the two groups (<i>P</i><0.01). However, multivariable analysis revealed no association between this difference and surgical approach (<i>β</i>=4.4, <i>P</i>>0.05). In the TPVR group, QRS duration was significantly shortened postoperatively (<i>P</i><0.01), with improvements in left ventricular end-diastolic volume index and cardiac index (both <i>P</i><0.01), but these improvements did not differ significantly from the SPVR group (all <i>P</i>>0.05). During the follow-up, one patient in each group developed infective endocarditis within 1-month post-procedure; both were successfully treated with antibiotics. No other major complications were observed.</p><p><strong>Conclusions: </strong>For patients with moderate-to-severe pulmonary regurgitation and RVSD, TPVR using the Venus-P valve effectively improves short-term pulmonary valve function and ventricular performance with a favorable safety profile, demonstrating potential as a minimally invasive alternative to SPVR .</p>","PeriodicalId":24007,"journal":{"name":"Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences","volume":" ","pages":"390-398"},"PeriodicalIF":0.0,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12176531/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Vitexin-4 ″-<i>O</i>-glucoside alleviates acetaminophen-induced acute liver injury].","authors":"Fan Dong, Shanglei Lai, Jiannan Qiu, Xiaobing Dou","doi":"10.3724/zdxbyxb-2024-0381","DOIUrl":"10.3724/zdxbyxb-2024-0381","url":null,"abstract":"<p><strong>Objectives: </strong>To explore the protective effect of vitexin-4 ″-<i>O</i>-glucoside (VOG) against acetaminophen-induced acute liver injury in mice and its underlying mechanism.</p><p><strong>Methods: </strong>C57BL/6 mice were randomly divided into 4 groups: normal control group, model control group, low-dose group of VOG (30 mg/kg), and high-dose group of VOG (60 mg/kg). Acute liver injury was induced by intraperitoneal injection of acetaminophen (500 mg/kg). VOG was administrated by gavage 2 h before acetaminophen treatment in VOG groups. The protective effect of VOG against acute liver injury was evaluated by detecting alanine transaminase (ALT), aspartate transaminase (AST) levels and hematoxylin and eosin staining. The malondialdehyde (MDA) content, superoxide dismutase (SOD) and catalase (CAT) activity in liver were detected to evaluate the hepatic oxidative stress. The expression levels of tumor necrosis factor (TNF)-α, <i>Il</i>-<i>1β</i>, and <i>Il</i>-<i>6</i> in liver were detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR). The expression levels of phosphorylated c-jun <i>N</i>-terminal kinase (JNK)/JNK, phosphorylated p38/p38, inositol-requiring enzyme 1 alpha (IRE-1α), X-box binding protein 1s (XBP1s), and glucose-regulated protein 78 (GRP78) in liver were detected by Western blotting. An endoplasmic reticulum stress model was established in AML-12 cells using tunicamycin. Cell viability was assessed using the CCK-8 assay, and the degree of cell damage was detected by lactate dehydrogenase (LDH) assay. The gene expression levels of <i>Ire</i>-<i>1α</i>, <i>Xbp1s</i>, and <i>Grp78</i> in the cells were detected using qRT-PCR.</p><p><strong>Results: </strong>In the animal experiments, compared with the model control group, VOG significantly improved plasma ALT and AST levels, liver MDA content, as well as SOD and CAT activities. VOG also reduced the expression levels of <i>Tnf</i>-<i>α</i>, <i>Il</i>-<i>1β</i>, and <i>Il</i>-<i>6</i> in the liver, and improved protein phosphorylation levels of JNK and p38, as well as the protein expression levels of IRE-1α, XBP1s, and GRP78. In cell experiments, VOG pretreatment enhanced cell viability, reduced LDH release and decreased the mRNA expression of <i>Ire</i>-<i>1α</i>, <i>Xbp1s</i>, and <i>Grp78</i>.</p><p><strong>Conclusions: </strong>VOG can suppress inflammation and oxidative stress, and alleviate acetaminophen-induced acute liver injury in mice by suppressing endoplasmic reticulum stress and modulating the MAPK signaling pathway.</p>","PeriodicalId":24007,"journal":{"name":"Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences","volume":" ","pages":"307-317"},"PeriodicalIF":0.0,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12176540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144217083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}